William M Deraedt
Impact in
- Hematology top 0.1%
- Multiple Myeloma Research and Treatments
- Oncology top 0.5%
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
Papers in
- Hematology 47
- Multiple Myeloma Research and Treatments 46
- Oncology 27
- CAR-T cell therapy research 18
- Cancer Treatment and Pharmacology 6
- Co-authors
- Helgi van de Velde (12 shared papers)Andrew Cakana (12 shared papers)Antonio Pierangelo Palumbo (6 shared papers)María‐Victoria Mateos (10 shared papers)Jordan Mark Schecter (14 shared papers)Tamás Masszi (5 shared papers)Ivan Špıčka (4 shared papers)Ming Qi (6 shared papers)
- Journals
- Blood (20 papers)Journal of Clinical Oncology (3 papers)Transplantation and Cellular Therapy (3 papers)Haematologica (3 papers)New England Journal of Medicine (3 papers)
- Partner nations
- United StatesBelgiumGermany
In The Last Decade
William M Deraedt
59 papers receiving 7.2k citations
William M Deraedt's Hit Papers
Peers
Comparison fields: 5 of 89
- Hematology 5.1k
- Oncology 4.1k
- Genetics 628
- Molecular Biology 3.3k
- Immunology 652
Countries citing papers authored by William M Deraedt
This map shows the geographic impact of William M Deraedt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William M Deraedt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William M Deraedt more than expected).
Fields of papers citing papers by William M Deraedt
This network shows the impact of papers produced by William M Deraedt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William M Deraedt. The network helps show where William M Deraedt may publish in the future.
Co-authors
The 25 scholars most cited alongside William M Deraedt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 61 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study Hit paper breakdown → | 2021 | 1360 |
| 2 | Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma Hit paper breakdown → | 2016 | 1253 |
| 3 | Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma Hit paper breakdown → | 2017 | 798 |
| 4 | Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study Hit paper breakdown → | 2011 | 794 |
| 5 | Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study Hit paper breakdown → | 2019 | 769 |
| 6 | Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up Hit paper breakdown → | 2022 | 510 |
| 7 | 2007 | 249 | |
| 8 | 2012 | 215 | |
| 9 | 2022 | 159 | |
| 10 | 2009 | 146 | |
| 11 | 2010 | 119 | |
| 12 | 2012 | 114 | |
| 13 | 2010 | 92 | |
| 14 | 2020 | 79 | |
| 15 | 2012 | 76 | |
| 16 | 2011 | 72 | |
| 17 | 2021 | 42 | |
| 18 | CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma Hit paper breakdown → | 2025 | 38 |
| 19 | 2011 | 32 | |
| 20 | 2015 | 32 |
About William M Deraedt
William M Deraedt is a scholar working on Hematology, Oncology, Genetics, Immunology and Molecular Biology, having authored 61 papers that have together received 7.4k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (46 papers), CAR-T cell therapy research (18 papers), Protein Degradation and Inhibitors (13 papers), Biosimilars and Bioanalytical Methods (7 papers), Cancer Treatment and Pharmacology (6 papers), Chronic Lymphocytic Leukemia Research (5 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and HIV/AIDS drug development and treatment (4 papers). The work is most often cited by research in Hematology (5.1k citations), Oncology (4.1k citations), Genetics (628 citations), Molecular Biology (3.3k citations) and Immunology (652 citations). William M Deraedt has collaborated with scholars based in United States, Belgium and Germany. Frequent co-authors include Helgi van de Velde, Andrew Cakana, Antonio Pierangelo Palumbo, María‐Victoria Mateos, Jordan Mark Schecter, Tamás Masszi, Ivan Špıčka, Ming Qi, Xiang Qin and Himal Amin. Their work appears in journals such as Blood, Journal of Clinical Oncology, Transplantation and Cellular Therapy, Haematologica and New England Journal of Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.